Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older

NCT00132808 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

581

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteopenia

Interventions

DRUG: Zoledronic Acid
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals